Finance

Lists
Why is TCRX down 4,97%?
Dive Deeper
TCRX:NASDAQ
Tscan Therapeutics Inc
0,14 $
-4,97%
(-0,0075) 1D
18 նոյ, 12:18:42 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TCRX...
Open
0,15 $
High
0,16 $
Low
0,14 $
Mkt. cap
9,79 մլն
Avg. vol.
527,79 հզր
Volume
204,96 հզր
52-wk high
1,47 $
52-wk low
0,14 $
EPS
-0,89 $
Beta
1,21
Shares outstanding
63,50 մլն
No. of employees
43
Open
0,15 $
High
0,16 $
Low
0,14 $
Mkt. cap
9,79 մլն
Avg. vol.
527,79 հզր
Volume
204,96 հզր
52-wk high
1,47 $
52-wk low
0,14 $
EPS
-0,89 $
Beta
1,21
Shares outstanding
63,50 մլն
No. of employees
43
News stories
From web sources and news partners
About Tscan Therapeutics Inc
CEO-
Employees43
Founded2018
HeadquartersՈւոլթեմ, Մասսաչուսեթս, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitetscan.com
Analyst ratings
Based on 4 analysts giving stock ratings to TCRX in the past 3 months
Hold
Buy
0
Hold
4
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TCRX in the last 3 months.
Highest
Current 0,14 $
1,00 $ (+596,86%)
Average
1,00 $ (+596,86%)
Lowest
1,00 $ (+596,86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Hold
Reiterated
-
-
11/13/2026
David Nierengarten
Wedbush
Hold
Maintained
1,00 $
+596,9%
11/13/2026
Sam Slutsky
LifeSci Capital
Hold
Downgraded
-
-
09/02/2026
Gil Blum
Needham
Hold
Downgraded
-
-
09/02/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
-
-
08/17/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
08/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
2,57 մլն
982,00 հզր
1,05 մլն
586,00 հզր
Cost of goods sold
18,44 մլն
21,90 մլն
23,40 մլն
-
Cost of revenue
18,44 մլն
21,90 մլն
23,40 մլն
-
Research and development expenses
-
-
-
25,29 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,99 մլն
8,22 մլն
8,14 մլն
8,33 մլն
Operating expense
5,99 մլն
8,22 մլն
8,14 մլն
33,62 մլն
Total operating expenses
24,42 մլն
30,12 մլն
31,54 մլն
33,62 մլն
Operating income
-21,86 մլն
-29,14 մլն
-30,49 մլն
-33,03 մլն
Other non operating income
-
-
-
-
EBT including unusual items
-22,98 մլն
-28,67 մլն
-30,36 մլն
-33,08 մլն
EBT excluding unusual items
-20,98 մլն
-28,67 մլն
-30,36 մլն
-33,08 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-22,98 մլն
-28,67 մլն
-30,36 մլն
-33,08 մլն
Net profit margin
-895,09%
-2 919,14%
-2 888,58%
-5 645,90%
Earnings per share
-0,18
-0,22
-0,23
-0,25
Interest and investment income
1,58 մլն
1,16 մլն
833,00 հզր
721,00 հզր
Interest expense
-702,00 հզր
-689,00 հզր
-699,00 հզր
-775,00 հզր
Net interest expenses
881,00 հզր
473,00 հզր
134,00 հզր
-54,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,14 մլն
-28,45 մլն
-29,79 մլն
-32,35 մլն
Gain or loss from assets sale
-
-
99,00 հզր
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps